Cholesterol-Lowering Drugs Market Key Highlights:
- Market Size (2024): USD 17.96 Billion
- Projected Market Size (2034): USD 23.90 Billion
- CAGR (2023-2034): 2.9%
Pricing Analysis:
- Price Growth
- Regional Variations
Market Historic Sales
- Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
- Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
- Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
- Analysis of revenue contributions from different manufacturers in the market.
Cholesterol-Lowering Drugs Market Definition
The cholesterol-lowering drugs market is an integral branch of the pharmaceutical industry. This industry deals in the manufacturing and distribution of drugs for lowering cholesterol in people. The different drugs used for lowering cholesterol include statins, bile acid sequestrants, nicotinic acid, PCSK9 inhibitors, and some others. The growing incidences of hyperlipidemia across the world have shaped the industry in a positive way. This market is likely to rise significantly with the growth of the healthcare industry across the world.
A rise in the number of patients suffering from cardiovascular diseases and hypercholesterolemia has increased the demand for effective medications, thereby boosting market growth. Also, the growing developments in the pharmaceutical industry, coupled with the rising use of cholesterol absorption inhibitors for the treatment of coronary artery diseases, is an integral driver of this industry. Moreover, the availability of effective cholesterol-lowering drugs in hospital pharmacies, online pharmacies, retail pharmacies, and some others, along with rising emphasis on developing new medicines, has driven the growth of the cholesterol-lowering drugs market.
Advancements in CRISPR gene editing therapy technology, along with the growing adoption of Pelacarsen and Olpasiran for lowering cholesterol in people worldwide, are expected to create ample growth opportunities for the market players in the future. In May 2022, Sun Pharma announced the launch of Brillo. Brillo is an oral drug used to reduce low-density lipoprotein (LDL) cholesterol in people.
Cholesterol-Lowering Drugs Market Segmentation:
By Type
- Statins
- Cholesterol Absorption Inhibitors
- Fibrates
- PCSK9 Inhibitors
By Application
Cholesterol-Lowering Drugs Market Companies:
- AstraZeneca
- Merck
- Pfizer
- Kowa
- Daiichi Sankyo
- AbbVie
- Novartis
- Sanofi
- Amgen
- Bristol-Myers Squibb.
For any questions about this dataset or to discuss customization options, please write to us at sales@statifacts.com
